# Stem cells weekly evidence review - November 2, 2026

Decision: substantive public article update warranted. Add a dated update covering a UK authorization extension, Japanese post-marketing implementation, disease-specific transplant trial evidence and a qualified orthopedic follow-up. Preserve the original deep report and previous updates.

Access date: 2026-11-02 PST, checked with system clock. Previous review: October 26. Literature entry-date and registry-update window: October 27-November 2 inclusive. This is targeted weekly monitoring, not a systematic review or certification of every jurisdiction's approvals. Entry date, publication date, authorization date and implementation date are different.

Article: https://managingexpectations.net/blog/articles/stem-cells-evidence-costs-risks-global-guide.html

## Selected findings and claim-to-source map

### 1. UK Casgevy authorization extends to eligible children aged five and over

Official source: MHRA, "MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders," published October 30, 2026. Authorization extension granted October 29 to Vertex Pharmaceuticals (Europe) Ltd.
https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders

Direct official HTML and alternate extraction both retrieved. Key passage: "The treatment was previously authorised in the UK for patients 12 and over"; the extension permits younger children meeting eligibility criteria. Conditions described are severe sickle-cell disease and transfusion-dependent beta-thalassemia. Do not imply that every child with either condition qualifies, that access/funding is automatic, or that a UK decision changes another country's label.

Casgevy uses the patient's gene-edited blood-forming stem cells and requires conditioning and specialist hospital care. The release identifies infection risk and other side effects. The notice says updated product information will be published within seven days; this run verifies the official authorization announcement, not the complete revised label. No treatment instructions or doses reproduced.

Evidence label: approved for narrow indications and eligible patient groups in the UK. This is a new regulatory milestone, not a new general stem-cell cure. Suggested edits: lead the weekly subsection with this finding and add a separate UK row to the regulatory table. The September pediatric research paragraph remains historical trial reporting, not a statement about current worldwide authorization.

Canadian comparator checked directly:
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1738688279298
Health Canada's decision summary describes its September 23, 2024 authorization for ages 12 and older. Its dynamically refreshed page-modified date is not a new decision date. No matching Canadian pediatric extension was verified; the public article says the UK change must not be assumed to apply elsewhere rather than claiming an exhaustive Canadian label audit.

### 2. Japan AMCHEPRY: first post-marketing study transplant, not a new approval

Primary company source: Sumitomo Pharma, Conference on Q2 FY2026 Financial Results, October 30, 2026, printed slides 15-16 (PDF pages 16-17).
https://www.sumitomo-pharma.com/ir/library/presentation/assets/pdf/eir20261030.pdf
Index: https://www.sumitomo-pharma.com/ir/library/presentation/

PDF extraction tool timed out; direct PDF download succeeded and text was extracted with pypdf. Key passage on slide 16: "The first patient transplantation was completed at Kyoto University Hospital in October 2026." It explicitly identifies a post-marketing Phase 4 study. This is company-reported implementation under Japan's existing conditional authorization, not independent evidence of improved symptoms in that patient. Do not describe it as unrestricted routine access, a new October approval, or the first human Parkinson's cell transplant ever.

Product and regulatory anchor: PMDA review report, PDF pages 1-4, and approved-information index.
https://www.pmda.go.jp/files/000281617.pdf
https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html

PMDA defines the product as allogeneic iPSC-derived dopaminergic neuronal progenitor cells, not undifferentiated pluripotent cells. The March 2026 approval is conditional and time-limited to seven years for motor symptoms inadequately responsive to conventional medicines including levodopa. Further efficacy evaluation and all-patient surveillance are required. Key passage: "the efficacy of the product should continue to be evaluated and confirmed after marketing approval."

Evidence label: conditionally approved for a narrow Japanese indication; implementation milestone reported by manufacturer. No newly demonstrated clinical outcome. AFP reporting opened as corroborating secondary coverage, not as the product-definition authority:
https://medicalxpress.com/news/2026-10-patient-stem-cell-treatment-parkinson.html

Suggested edit: brief dated paragraph, retaining existing Japan table approval caveats. Secondary reports about returning to work are not used to infer graft effectiveness or publish patient details.

### 3. Leukemia transplant conditioning: randomized phase 3 result, serious risks remain

Zhongli Hu et al. "Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A-rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial." The Lancet Haematology, November 2026;13(11):e810-e821. PMID 42956759. DOI 10.1016/S2352-3026(26)00250-4. PubMed entry October 29.
https://pubmed.ncbi.nlm.nih.gov/42956759/

Official NCBI XML and PubMed abstract retrieved; publisher full text returned 403. Abstract-level appraisal only, not a full protocol or adverse-event-table audit. Eight Chinese centres, 130 randomized patients, 65 per group, eligibility ages 14-65. Adding decitabine to the comparison conditioning regimen was associated with two-year cumulative relapse of 12% versus 29% (hazard ratio 0.41, 95% CI 0.20-0.87). The trial was open-label, narrowly disease-specific and does not establish a general cancer cure or a new product approval.

Serious safety context: grade 3-5 infections in 42% versus 38%; acute GVHD in 35% versus 34%; four versus five deaths from adverse events, including one regimen-related toxicity death in each group. Do not equate all adverse-event deaths with proven causation by the added drug. Authors declare no competing interests; public Chinese research funding listed. The abstract does not establish an overall-survival advantage.

Evidence label: randomized phase 3 evidence for a specific transplant-conditioning strategy. Suggested edit: include relapse result and serious adverse events without administration schedules, recommendations or claims of a proven survival gain.

### 4. Knee cartilage: encouraging five-year results with selection and attrition limits

Yong-Beom Park and Chul-Won Ha. "More Durable Cartilage Repair and Better Clinical Outcomes at 5 Years Using Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronate Composite Implantation Versus Microfracture for Knee Osteoarthritis." Arthroscopy, electronic publication October 31, 2026. PMID 42965407. DOI 10.1002/arj.70706.
https://pubmed.ncbi.nlm.nih.gov/42965407/

NCBI XML and PubMed abstract retrieved. Wiley full text returned 403; complete safety and conflict-of-interest review not available. This is a retrospective subset analysis of an earlier phase 3 trial, not a newly randomized five-year study. Original trial: 89 patients; analysis subset: 64; five-year completers: 48. The intervention is surgical cord-blood-derived MSC/hyaluronate composite implantation, not an interchangeable cash-pay injection or IV infusion.

Authors report better pain/function scores and a higher proportion meeting their longitudinal MRI-defined durable-repair criterion. Important counterweights: ordinary MRI repair scores did not differ between groups, and proportions meeting minimal clinically important improvement thresholds were not significantly different. Selection and loss to follow-up limit inference. Do not reduce this to "stem cells regrow arthritic knees" or infer a new FDA/Health Canada approval.

Evidence label: promising product/procedure-specific long-term comparative evidence, Level III retrospective study. Suggested edit: short balanced weekly paragraph; retain general orthopedic caution and prices unchanged.

## Required source checks and unchanged conclusions

### FDA
- Approved cellular and gene therapy list: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
- Regenerative-medicine consumer guidance: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
- Safety index: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2026-safety-and-availability-communications

Direct requests returned short 404s; alternate web extraction recovered substantive official pages. The safety index's latest displayed entries remain October 22-23 blood-donation/BabyBIG items, not a new stem-cell action. The list contains Tregzi, Ryoncil, Casgevy and other indication-specific products. No new weekly stem-cell approval established by this screen. The June 2021 consumer page's historic "only cord blood" footnote is not a current approvals inventory. FDA registration or a registry listing is not marketing approval.

### Health Canada
- Autologous policy: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html
- Advisory: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized
- Casgevy decision summary above.

All retrieved directly. The advisory is dated May 15, 2019; its old product count is not a current inventory. Targeted searches were noisy and were broadened; no new Canadian cell-therapy warning or policy change verified. Autologous origin alone is not evidence of safety or exemption. Canadian table unchanged.

### NIH/NCI and ClinicalTrials.gov
- https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant
- https://clinicaltrials.gov/api/v2/studies

NCI page retrieved: established specialist-transplant context remains. Registry query: (stem cell OR mesenchymal OR iPSC OR exosome) AND AREA[LastUpdatePostDate]RANGE[2026-10-27,2026-11-02]. All returned pages collected: 180 unique records. Broad matches include eligibility references and non-cell medicines; this is not 180 new cell trials. Distinguish updated records from first-posted results.

New result-posting leads include BMT4me (NCT05515497, October 27), TEACH (NCT03504241, October 29), Immune Disorder HSCT Protocol (NCT01821781, October 27) and Robot Rehab (NCT05275543, October 28). These remain registry-reported evidence, not regulator endorsements. Detailed result modules for the first three were retrieved for triage, not fully adjudicated. No additional efficacy headline selected; the disease-specific published phase 3 trial above is the stronger public addition. Registry data are saved locally, not deployed, because they include protocols and dosing.

### ISSCR and AAOS
- https://www.isscr.org/guidelines
- https://www.isscr.org/isscr-news
- https://www.isscr.org/public-policy
- https://www.orthoinfo.org/treatment/use-of-stem-cells-in-orthopaedics

Direct retrieval succeeded. ISSCR guidelines still identify August 2025 version 1.2, with a targeted embryo-model update; displayed news includes October 19-22 symposium/directory announcements rather than a new clinical guideline. AAOS guidance continues to caution about uncertain orthopedic evidence. The new knee paper does not change that into endorsement of generic clinic injections.

### Global regulation and clinic-market monitoring
- EU: https://www.ema.europa.eu/en/news retrieved. October 30 PRAC headline concerns Deanxit and immunoglobulin safety, not a newly verified stem-cell approval. Existing EMA cautions in the report retained.
- UK: https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk retrieved; specific new Casgevy authorization verified separately above.
- Japan: PMDA translated index and AMCHEPRY report retrieved. Stemirac full-approval-conversion reporting still describes panel backing/anticipated final approval. No newly verified final ministry decision; do not upgrade its status from snippets. Secondary lead: https://www.bioworld.com/articles/735030-japan-backs-nipros-stemirac-for-first-full-approval-under-cea
- Singapore: https://www.hsa.gov.sg/ctgtp/overview/regulatory-overview/ direct 403; alternate extraction retrieved Class 1/Class 2 framework. https://www.hsa.gov.sg/announcements/ opened through extraction, including November 2 side-effect-reporting and November 1 non-cell-drug recall headlines. No substantive new cell-therapy rule verified. Inconsistent page-update metadata across retrievals are not evidence of a new law.
- Australia: https://www.tga.gov.au/news/news-articles/stem-cell-treatments-and-regulation-quick-guide-consumers direct timeout; alternate extraction recovered historic guidance. https://www.tga.gov.au/news/safety-updates opened; latest displayed item concerns vaccine reconstitution. Historic consumer wording is not a complete current approvals inventory. No new relevant action verified.
- Mexico/Panama/Cayman: search results largely clinic marketing or older material; no new verified regulator action or comparable price change. An academic Panama market critique was opened: https://pmc.ncbi.nlm.nih.gov/articles/PMC13476878 (July 23, 2026). It concerns unproven-intervention marketing and enforcement gaps, not a new November warning; not presented as a current clinic-license audit. No clinic endorsement or claims that all overseas clinics are illegal.

## Literature breadth and unselected leads

PubMed query: (stem cell OR mesenchymal OR iPSC OR exosome OR hematopoietic transplantation) AND (trial OR safety OR adverse OR Parkinson OR diabetes OR spinal cord OR arthritis OR autoimmune OR cancer) AND (2026/10/27:2026/11/02[EDAT]). Retrieved 491 records and their abstracts. Keyword triage selected 67 records for further screening. This is broad discovery plus selective appraisal, not full review of every paper.

- Progressive MS review, PMID 42965998, DOI 10.1016/j.jcyt.2026.102935: clinical benefit remains unestablished despite mechanisms and early signals. https://pubmed.ncbi.nlm.nih.gov/42965998/
- Intranasal neurologic biologics review, PMID 42964121, DOI 10.3389/fddev.2026.1969111: mostly uncontrolled cohorts and heterogeneous products; no reported treatment-related serious events does not establish rare-event safety. https://pubmed.ncbi.nlm.nih.gov/42964121/
- Autism phase I study, PMID 42958455, DOI 10.1186/s13287-026-05122-1: five children, open-label, six-month follow-up; all had transient adverse events. Not proof of efficacy or broad safety. No protocol or cure claim reproduced. https://pubmed.ncbi.nlm.nih.gov/42958455/
- Disc MSC/exosome cohort, PMID 42940041, DOI 10.3390/biomedicines14102235: association with function, not a demonstrated added pain benefit; observational findings do not establish exosome efficacy or approval. https://pubmed.ncbi.nlm.nih.gov/42940041/
- Diabetes, spinal cord, iPSC, cancer and exosome matches include preclinical mechanisms, reviews and unrelated drugs. No general cure or clinical-category upgrade inferred.
- Miami's October 19 arterial knee-cell trial announcement was opened as a catch-up lead, not selected as a new weekly result. It says enrollment has not begun and describes safety/feasibility, not proven benefit: https://news.med.miami.edu/artery-delivered-stem-cells-knee-osteoarthritis-trial-2/
- No independently verified new public/celebrity outcome selected. Testimony remains anecdotal. Japanese procedure reporting is not evidence of long-term recovery.

## Changes, non-changes and publication scope

Add November 2 subsection after medical caution; update article's review date; add UK regulatory row with precise authorization date and caveats. Add article/source-note sitemap lastmod entries. Keep all original report sections and prior updates intact. Health page remains untouched because no new report/card is being added. Prices, assets and stylesheet unchanged.

Local pre-edit backups: _local-backups/stem-cells-2026-11-02/. Local article, sitemap and Health page were byte-identical to remote versions before edits. DNS and headers confirmed Hostinger shared hosting at 195.35.15.247, not KillerWolf. Deployment scope: only article, this source note and sitemap, each to its correct directory. Remote backups and verification are recorded in the local evidence folder; this note is not itself a deployment-success assertion.

Evidence folder (local only): research/health/stem-cells-weekly-evidence-2026-11-02/. Contains retrieval logs, official snapshots, PDFs, NCBI XML and registry JSON. Full-text access limitations: Wiley and Lancet returned 403; selected paper appraisals rely on official abstracts. No browser-vision tool available; use parsed HTML, link checks, remote byte verification and live HTTP read-back.

Next priorities: revised UK product label, any separately confirmed Canadian age extension, final Japanese Stemirac decision, long-term iPSC outcomes and adequately controlled trials rather than promotional summaries.

Medical boundary: education and source review only; not medical advice, diagnosis, dosing, treatment guidance, clinic endorsement or a recommendation to travel.